Last year's bear market dragged down many stocks. And CRISPR Therapeutics (NASDAQ: CRSP) wasn't an exception. The biotech company was down by 46%. But what makes this loss surprising is the fact that CRISPR is closer than ever to a major milestone -- one that could highlight the strength of its science and result in significant revenue.

I'm talking about the potential approval of CRISPR's very first product. CRISPR and partner Vertex Pharmaceuticals have applied for authorization of exa-cel, a candidate to treat blood disorders. If all goes well, Wall Street's average forecast for a 70% jump in CRISPR shares within the coming 12 months could happen.

Let's take a closer look at what we may expect from this exciting stock.

Continue reading

Source Fool.com